Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [921]

Atezolizumab as monotherapy or in combination with cobimetinib in biliary tract...

Dr Mark Yarchoan - John Hopkins Medicine, Baltimore, USA

Atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers ( Dr Mark Yarchoan - John Hopkins Medicine, Baltimore, USA )

The impact of COVID-19 on ALL patients in Spain

Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

The impact of COVID-19 on ALL patients in Spain ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as...

Prof Bruno Sangro - University of Navarra, Pamplona, Spain

CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as first-line treatment in aHCC ( Prof Bruno Sangro - University of Navarra, Pamplona, Spain )

Background of the KEYNOTE-158 trial for pembrolizumab in advanced mesothelioma

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

Background of the KEYNOTE-158 trial for pembrolizumab in advanced mesothelioma ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )

Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with...

Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA

$Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL ( Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA )$

New CAR T therapy for relapsed and refractory ALL

Dr Claire Roddie - University College London, London, UK

$New CAR T therapy for relapsed and refractory ALL ( Dr Claire Roddie - University College London, London, UK )$

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA

$Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma ( Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA )$

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1...

Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis ( Dr Simon Renders - German Cancer Research Center (DKFZ), Heidelberg, Germany )

CTC count as a prognostic marker for androgen deprivation plus orteronel or...

Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA

CTC count as a prognostic marker for androgen deprivation plus orteronel or bicalutamide in mCSPC ( Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA )

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation...

Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer ( Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France )

AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in...

Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany

AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurrent ovarian cancer ( Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany )

Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based...

Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy

Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer ( Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy )

More from ecancer